Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that Dr. Ingrid Delaet will join the company’s executive management team as Chief Regulatory Officer effective October 1, leading the regulatory affairs, quality assurance, medical writing, and program management teams. Dr Ingrid Delaet has served as Vice President of Regulatory Affairs at Neurocrine since January 2021.
“Ingrid’s deep experience in regulatory affairs will be invaluable to Neurocrine as we work to advance our pipeline in our quest to relieve suffering for people with great needs, but few options,” said Kevin Gorman, Ph.D., Chief Executive Officer of Neurocrine Biosciences. “We are thrilled Ingrid is joining the management team to help lead our efforts to discover and develop life-changing treatments for patients with under-addressed neurological, neuroendocrine, and neuropsychiatric disorders.”
Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016. Between 1997 and 2016, she held various positions of increasing responsibility at Bristol-Myers Squibb in the United States, first in Clinical Research and Development and then in Global Regulatory Affairs, where she served as Therapeutic Area Lead for Immunology. Dr. Delaet started her career in the pharmaceutical industry in Belgium, where she held positions in clinical research at CellPro and Wyeth-Ayerst Research. She received her Ph.D. in Immunology and her M. Sc. in Pharmaceutical Sciences from The Free University of Brussels, Belgium.